53 results on '"Nurmohamed, Michael T"'
Search Results
2. Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study
3. Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor
4. Predictors for response to electronic patient-reported outcomes in routine care in patients with rheumatoid arthritis: a retrospective cohort study
5. Effect of TNF inhibitors on arterial stiffness and intima media thickness in rheumatoid arthritis: a systematic review and meta-analysis
6. Facilitators and barriers to adhere to monitoring disease activity with ePROs: a focus group study in patients with inflammatory arthritis
7. Effect of anti-inflammatory therapy on vascular biomarkers for subclinical cardiovascular disease in rheumatoid arthritis patients
8. Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study
9. Correction to: Coagulation in gout: is there a link with disease activity?
10. Coagulation in gout: is there a link with disease activity?
11. Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis—a spin-off study of the NORD-STAR randomized clinical trial
12. Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial
13. Publisher Correction: Cardiovascular effects of approved drugs for rheumatoid arthritis
14. Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials
15. Cardiovascular effects of approved drugs for rheumatoid arthritis
16. Current understanding and future perspectives of brain–heart–kidney axis in psoriatic arthritis
17. Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory Diseases
18. Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial
19. Can personalized use of NSAIDs be a reality in the clinic?
20. Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice
21. Multicentric reticulohistiocytosis: a case report
22. Assessment of aortic stiffness in patients with ankylosing spondylitis using cardiovascular magnetic resonance
23. Cardiovascular safety of celecoxib, naproxen and ibuprofen
24. Erratum to: Unexpected arterial wall and cellular inflammation in patients with rheumatoid arthritis in remission using biological therapy: a cross-sectional study
25. Unexpected arterial wall and cellular inflammation in patients with rheumatoid arthritis in remission using biological therapy: a cross-sectional study
26. Cardiovascular comorbidity in rheumatic diseases
27. Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study
28. Erratum to: Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice
29. Cardiovascular risk management in patients with active Ankylosing Spondylitis: a detailed evaluation
30. Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice
31. Rheumatoid arthritis and metabolic syndrome
32. Biologics, cardiovascular effects and cancer
33. Is atherosclerosis an autoimmune disease?
34. Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study
35. Increased risk for chronic comorbid disorders in patients with inflammatory arthritis: a population based study
36. Cardiovascular risk management in rheumatoid arthritis: are we still waiting for the first step?
37. Cardiovascular disease prevalence in patients with inflammatory arthritis, diabetes mellitus and osteoarthritis: a cross-sectional study in primary care
38. Cardiovascular and Cerebrovascular Diseases in Ankylosing Spondylitis: Current Insights
39. Validated methods for assessment of subclinical atherosclerosis in rheumatology
40. Interferon type I signature may predict non response upon rituximab in rheumatoid arthritis patients
41. Moving instead of asking? Performance-based tests and BASFI-questionnaire measure different aspects of physical function in ankylosing spondylitis
42. Are NSAIDs safe to use in post-MI patients?
43. The increased cardiovascular risk in rheumatoid arthritis: when does it start?
44. Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study
45. Newer Biological Agents in the Treatment of Rheumatoid Arthritis
46. Use of methotrexate therapy is not associated with decreased prevalence of metabolic syndrome
47. Are biologics more effective than classical disease-modifying antirheumatic drugs?
48. Do C-reactive protein levels help predict onset of rheumatoid arthritis in women?
49. Efficacy, Tolerability and Cost Effectiveness of Disease-Modifying Antirheumatic Drugs and Biologic Agents in Rheumatoid Arthritis
50. Cardiovascular Risk Profile of Antirheumatic Agents in Patients with Osteoarthritis and Rheumatoid Arthritis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.